Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery advancement and marketing of innovative treatments particularly for cystic fibrosis CF The company offers a range of approved medications for CF patients including SYMDEKOSYMKEVI ORKAMBI and KALYDECO which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene Additionally they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation Beyond its established CF therapies Vertex maintains a robust and diverse clinical pipeline This includes VX864 currently in Phase 2 for alpha1 antitrypsin AAT deficiency VX147 also in Phase 2 addressing APOL1mediated focal segmental glomerulosclerosis FSGS and other serious kidney conditions VX880 a potential treatment for Type 1 Diabetes undergoing Phase 12 trials VX548 a NaV18 inhibitor in Phase 2 for various forms of acute neuropathic and musculoskeletal pain and CTX001 which is in Phase 3 development for severe sickle cell disease SCD and transfusiondependent betathalassemia TDT The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States while international sales are facilitated via a network of specialty distributors retail chains hospitals and clinics Vertex also engages in numerous strategic collaborations with partners such as Affinia Therapeutics Arbor Biotechnologies CRISPR Therapeutics Kymera Therapeutics Mammoth Biosciences Moderna Obsidian Therapeutics Skyhawk Therapeutics Ribometrix Genomics plc Merck KGaA and XChem Established in 1989 Vertex Pharmaceuticals is headquartered in Boston Massachusetts